Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds antigen or epitope whose amino acid sequence is...
Reexamination Certificate
2007-03-20
2007-03-20
Ewoldt, G. R. (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds antigen or epitope whose amino acid sequence is...
C424S133100, C424S135100, C424S141100, C424S145100, C530S387900, C530S388100, C530S388240
Reexamination Certificate
active
10384893
ABSTRACT:
Antibodies to a novel family of TGF-β binding proteins are disclosed, for use in methods of altering bone density and bone mineralization, which methods are applicable to the treatment of diseases including osteopenia and osteoporosis.
REFERENCES:
patent: 4376110 (1983-03-01), David et al.
patent: 5070108 (1991-12-01), Margolis
patent: 5453492 (1995-09-01), Bützow et al.
patent: 5780263 (1998-07-01), Hastings et al.
patent: 5811238 (1998-09-01), Stemmer et al.
patent: 5830721 (1998-11-01), Stemmer et al.
patent: 5837458 (1998-11-01), Minshull et al.
patent: 6395511 (2002-05-01), Brunkow et al.
patent: WO 91/13152 (1991-09-01), None
patent: WO 92/06693 (1992-04-01), None
patent: WO 95/30003 (1995-09-01), None
patent: WO 02/24888 (2002-03-01), None
The Merck Manual-Second Home Edition, chapter 61, Paget's disease of bone, pp. 1-3, downloaded Apr. 19, 2005.
Groeneveld et al., “Bone morphogenic proteins in human bone regeneration” (2000) Eur. J. Endocrinol. 142:9-21.
Piek et al. “Specificity, diversity and regulation in TGF-beta superfamily signaling” (1999) FASEB J. 13:2105-2124.
Kusu et al. “Sclerostin is a novel secreted osteoclast-derived bone morphogenic protein antagonist with unique ligand specificity” (2003) J. Biol. Chem. 278:24113-24117.
Birren et al., EMBL Sequence Database, Accession No. AC003098, Nov. 14, 1997.
Bonaldo et al., “Normalization Subtraction: Two Approaches to Facilitate Gene Discovery,”Genome Res. 6(9):791-806, 1996.
Bonaldo et al., EMBL Sequence Database, Accession No. AI113131, Sep. 4, 1998.
Fujiwara et al., Genbank Accession No. D79813, Feb. 9, 1996.
Hillier et al., EMBL Sequence Database, Accession No. AA393939, May 19, 1997.
Hillier et al., Genbank Accession No. AA393768, Apr. 24, 1997.
Hsu et al., “TheXenopusDorsalizing Factor Gremlin Identifies a Novel Family of Secreted Proteins that Antagonize BMP Activities,”Molecular Cell 1: 673-683, Apr. 1998.
Iemura et al., “Direct Binding of follistatin to a complex of bone-morphogenetic protein and its receptor inhibits ventral and epidermal cell fates in earlyXenopusembryo,”Proc. Natl. Acad. Sci. USA 95: 9337-9342, Aug. 1998.
Khosla and Riggs, “Concise Review for Primary-Care Physicians. Treatment Options for Osteoporosis,”Mayo Clin Proc 70: 978-982, 1995.
Riggs, “Overview of Osteoporosis,”West J. Med. 154: 63-77, Jan. 1991.
Genbank Accession No. AAB33865, May 27, 1995.
Genbank Accession No. CAA88759, Jan. 8, 1997.
Genbank Accession No. U25110, Feb. 2, 1996.
Genbank Accession No. Z48923, Jan. 8, 1997.
Bendayan, M., “Possibilities of False Immunocytochemical Results Generated by the Use of Monoclonal Antibodies: The Example of the Anti-proinsulin Antibody,” J. Histochem. Cytochem. (1995) 43(9): 881-886.
Bost et al., “Antibodies Against a Peptide Sequence within the HIV Envelope Protein Crossreacts with Human Interleukin-2,” Immunol. Invest. (1988) 17(6&7):577-586.
Brunkow et al., “Bone Dysplasia Sclerosteosis Results from Loss of the SOST Gene Product, a Novel Cysteine Knot-Containing Protein.” Am. J. Hum. Genet. (2001) 68:577-589.
Campbell et al., “Totipotency or Multipotentiality of Cultured Cells: Applications and Progress,” Theriogenology (1997) 47:63-72.
Colman, P.M., “Effects of Amino Acid Sequence Changes on Antibody-Antigen Interactions,” Research in Immunology (1994) 145:33-36.
Durham et al., “Alterations in Insulin-Like Growth Factor (IGF)-Dependent IGF-Binding Protein-4 Proteolysis in Transformed Osteoblastic Cells,” Endocrinology (1995) 136(4):1374-1380.
Harlow et al., “Antibodies: A Laboratory Manual,” (1988) pp. 141-157, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
Hay et al., “ATCC Cell Lines and Hybridomas,” American Type Culture Collection 8thed., (1994) pp. 149, 258 and 428, Rockville, MD.
Hoffman et al., “BMP Signaling Pathways in Cartilage and Bone Formation,” Critical Review in Eukaryotic Gene Expression (2001) 11(1-3):23-45.
Kawabata et al., “Signal Transduction by Bone Morphogenetic Proteins,” Cytokine & rowth Factor Reveiws (1998) 9(1):49-61.
Lian et al., “Bone Formation: Osteoblast Lineage Cells, Growth Factors, Matrix Proteins, and the Mineralization Process,” Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 4thEdition (1999) 14-29.
Mullins et al., “Perspectives Series: Molecular Medicine in Genetically Engineered Animals; Transgenesis in the Rat and Larger Mammals,” J. Clin. Invest. (1996) 97(7):1557-1560.
Nicolas et al., “An Age-Related Decrease in the Concentration of Insulin-Like Growth Factor Binding Protein-5 in Human Cortical Bone,” Calcif. Tissue Int. (1995) 57:206-212.
Oshima et al., “TGF-β Receptor Type II Deficiency Results in Defects of Yolk Sac Hematopoiesis and Vasculogenesis,” Developmental Biology (1996) 179:297-302.
Pittenger et al., “Multilineage Potential of Adult Human Mesenchymal Stem Cells,” Science (1999) 284:143-147.
Pockwinse et al., “Expression of Cell Growth and Bone Specific Genes at Single Cell Resolution During Development of Bone Tissue-Like Organization in Primary Osteoblast Cultures,” Journal of Cellular Biochemistry (1992) 49:310-323.
Sali et al., “Comparative Protein Modelling by Satisfaction of Spatial Restraints,” J. Mol. Biol. (1993) 234:779-815.
Schlunegger et al., “Refined Crystal Structure of Human Transforming Growth Factor β2 at 1.95 Å Resolution,” J. Mol. Biol. (1993) 231:445-458.
Schmitt et al., “Bone Morphogenetic Proteins: An Update on Basic Biology and Clinical Relevance,” Journal of Orthopaedic Research (1999) 17:269-278.
Serra et al., “Expression of a Truncated, Kinase-Defective TGF-β Type II Receptor in Mouse Skeletal Tissue Promotes Terminal Chondrocyte Differentiation and Osteoarthritis,” J Cell Biol. (1997) 139(2):541-552.
Smith, “TGF β Inhibitors, New and Unexpected Requirements in Vertebrate Development,” TIG (1999) 15(1):3-5.
Zimmerman et al., “The Spemann Organizer Signal noggin Binds and Inactivates Bone Morphogenetic Protein 4,” Cell (1996) 86(4):599-606.
Brunkow Mary E
Galas David J
Kovacevich Brian
Mulligan John T
Ness Jeffrey Van
Darwin Discovery Ltd.
Ewoldt G. R.
Szperka Michael
LandOfFree
Methods for modulating bone mineralization does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for modulating bone mineralization, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for modulating bone mineralization will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3771566